Tvardi Therapeutics (TVRD) shares Q3 2025 results and highlights via 8-K

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results and business highlights for the fiscal quarter ended September 30, 2025. The company issued the press release on November 13, 2025, and attached it as Exhibit 99.1.

The information about results and highlights is furnished under Item 2.02 of the Exchange Act and is not deemed filed or incorporated by reference into other SEC filings. The report also includes an Inline XBRL cover page as Exhibit 104.

false 0001346830 0001346830 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 13, 2025

TVARDI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36279		75-3175693
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
3 Sugar Creek Ctr. Blvd. Suite 525 Sugar Land, Texas				77478
(Address of principal executive offices)				(Zip Code)

Registrant's telephone number, including area code: (713) 489-8654

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TVRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter ended September 30, 2025. A copy of the Company’s press release dated November 13, 2025 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and the accompanying Exhibit 99.1 is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued on November 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TVARDI THERAPEUTICS, INC.
Date: November 13, 2025	By:	/s/ Imran Alibhai
	Name:	Imran Alibhai
	Title:	Chief Executive Officer

FAQ

What did Tvardi Therapeutics (TVRD) announce in this Form 8-K?

Tvardi Therapeutics furnished a press release announcing its financial results and business highlights for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and provides the detailed quarterly information.

Which period do Tvardi Therapeutics' latest results in this 8-K cover?

The results discussed relate to the fiscal quarter ended September 30, 2025. Tvardi Therapeutics issued a press release on November 13, 2025 describing financial results and business highlights for that quarter, and furnished it as Exhibit 99.1 to this report.

Is Tvardi Therapeutics' earnings press release in this 8-K considered filed with the SEC?

No, the earnings press release and related information are furnished under Item 2.02 and are not deemed filed under Section 18 of the Exchange Act. They also are not automatically incorporated by reference into other Tvardi Therapeutics SEC filings.

Where can investors find Tvardi Therapeutics' detailed quarterly financial results?

Investors can review Tvardi Therapeutics’ detailed quarterly financial results and business highlights in the press release attached as Exhibit 99.1. The Form 8-K itself mainly identifies the exhibit and clarifies the legal treatment of the furnished information.

What exhibits are included with Tvardi Therapeutics' November 13, 2025 Form 8-K?

The filing includes Exhibit 99.1, a press release issued November 13, 2025 detailing quarterly results and business highlights, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document for the Tvardi Therapeutics 8-K.

Who signed Tvardi Therapeutics' November 13, 2025 Form 8-K?

The Form 8-K was signed on behalf of Tvardi Therapeutics, Inc. by Imran Alibhai, the company’s Chief Executive Officer. His electronic signature appears on the signature page dated November 13, 2025 as the duly authorized representative.